
NYSEHealthcareDrug Manufacturers - Specialty & Generic
أحدث البيانات المتاحة
74.77 US$
+1.69 US$ · +2.31%
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
الإغلاق السابق
74.77 US$
+1.69 US$ · +2.31%
قبل افتتاح السوق
75.15 US$
+0.38 US$ · +0.51%
12 أكتوبر، 8:24 ص ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
شراء
تقييم
96
قيمة جذابة جدًا
المشاعر
66
صعودي
المخاطر
43
مخاطر أعلى من المعتاد
الزخم
25
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
نطاق اليوم
السعر الحالي 74.77 US$
نطاق 52 أسبوعًا
السعر الحالي 74.77 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 9.47 مليار USD | 9.26 مليار USD | 8.54 مليار USD | 8.08 مليار USD | 7.78 مليار USD |
| تكلفة البضاعة المباعة | 2.79 مليار USD | 2.86 مليار USD | 2.71 مليار USD | 2.6 مليار USD | 2.46 مليار USD |
| الربح الإجمالي | 6.67 مليار USD | 6.4 مليار USD | 5.83 مليار USD | 5.48 مليار USD | 5.31 مليار USD |
| البحث والتطوير | 698 مليون USD | 686 مليون USD | 614 مليون USD | 539 مليون USD | 508 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 2.38 مليار USD | 2.32 مليار USD | 2.15 مليار USD | 2.01 مليار USD | 2 مليار USD |
| نفقات التشغيل | 3.08 مليار USD | 3 مليار USD | 2.77 مليار USD | 2.55 مليار USD | 2.51 مليار USD |
| دخل الفوائد | 93 مليون USD | 106 مليون USD | 105 مليون USD | 50 مليون USD | 6 مليون USD |
| مصاريف الفوائد | 243 مليون USD | 242 مليون USD | 258 مليون USD | 237 مليون USD | 236 مليون USD |
| الاستهلاك والإطفاء | 487 مليون USD | 497 مليون USD | 491 مليون USD | 465 مليون USD | 448 مليون USD |
| الدخل التشغيلي | 3.6 مليار USD | 3.39 مليار USD | 3.07 مليار USD | 2.93 مليار USD | 2.8 مليار USD |
| صافي الدخل | 2.67 مليار USD | 2.49 مليار USD | 2.34 مليار USD | 2.11 مليار USD | 2.04 مليار USD |
تم تحديث حقائق الشركة 12 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.